BR0313290A - Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produção - Google Patents
Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produçãoInfo
- Publication number
- BR0313290A BR0313290A BR0313290-0A BR0313290A BR0313290A BR 0313290 A BR0313290 A BR 0313290A BR 0313290 A BR0313290 A BR 0313290A BR 0313290 A BR0313290 A BR 0313290A
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- group etc
- alkyl group
- pyrazole
- chem
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"DERIVADO DE PIRAZOL, COMPOSIçãO MEDICINAL CONTENDO O MESMO, USO MEDICINAL DELE, E INTERMEDIáRIO PARA A SUA PRODUçãO". Um derivado de pirazol, representado pela fórmula geral (I) (em que R^ 1^ é H, alquila C~ 1-6~ opcionalmente substituído etc.; um de Q e T é o grupo da fórmula (II) ou da fórmula (III) e o outro é alquila C~ 1-6~ opcionalmente substituído etc.; R^ 2^ é H, halogênio, OH, alquila C~ 1-6~ opcionalmente substituído etc.; X é um ligação simples, O ou S; Y é urna ligação simples, alquileno C~ 1-6~ etc.; Z é CO OU SO~ 2~; cada um de R^ 4^ e R^ 5^ é H, alquila C~ 1-6~ opcionalmente substituído etc.; e cada um de R^ 3^, R^ 6^ e R^ 7^ é H, halogênio etc.), um sal farmaceuticamente aceitável do derivado ou um promedicamento de qualquer um dos dois. Eles têm uma atividade inibidora excelente de SGLT1 humano e são úteis como um agente preventivo ou terapêutico para doenças atribuíveis à hiperglicemia tais como diabetes, complicações de diabetes e obesidade.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002232074 | 2002-08-08 | ||
JP2002321729 | 2002-11-05 | ||
PCT/JP2003/010048 WO2004014932A1 (ja) | 2002-08-08 | 2003-08-07 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR0313290A true BR0313290A (pt) | 2005-07-05 |
BRPI0313290B1 BRPI0313290B1 (pt) | 2016-12-06 |
Family
ID=31719857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313290A BRPI0313290B1 (pt) | 2002-08-08 | 2003-08-07 | derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal |
Country Status (19)
Country | Link |
---|---|
US (2) | US7375087B2 (pt) |
EP (1) | EP1544208B1 (pt) |
JP (1) | JP4540475B2 (pt) |
KR (1) | KR100985502B1 (pt) |
AT (1) | ATE469161T1 (pt) |
AU (1) | AU2003254847B2 (pt) |
BR (1) | BRPI0313290B1 (pt) |
CA (1) | CA2494179C (pt) |
DE (1) | DE60332743D1 (pt) |
ES (1) | ES2345250T3 (pt) |
HK (1) | HK1082743A1 (pt) |
IL (1) | IL166748A0 (pt) |
MX (1) | MXPA05001549A (pt) |
NO (1) | NO330456B1 (pt) |
NZ (1) | NZ538117A (pt) |
PL (1) | PL213095B1 (pt) |
RU (1) | RU2356906C2 (pt) |
TW (1) | TW200413401A (pt) |
WO (1) | WO2004014932A1 (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000025598A1 (en) | 1998-11-03 | 2000-05-11 | Dandy A/S | Sucrose fatty acid esters for use as increased release of active ingredients |
MXPA05001549A (es) * | 2002-08-08 | 2005-05-05 | Kissei Pharmaceutical | Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion. |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
AU2003262262A1 (en) * | 2002-08-27 | 2004-03-19 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof |
JPWO2004050122A1 (ja) * | 2002-12-04 | 2006-03-30 | キッセイ薬品工業株式会社 | 高血糖症に起因する疾患の予防又は治療剤 |
AU2003289440A1 (en) * | 2002-12-25 | 2004-07-22 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
JP5086643B2 (ja) * | 2004-11-18 | 2012-11-28 | キッセイ薬品工業株式会社 | 1−置換−3−(β−D−グリコピラノシル)含窒素ヘテロ環化合物、及びそれを含有する医薬 |
FR2878523B1 (fr) * | 2004-11-30 | 2007-09-14 | Oreal | Nouveaux derives sulfamides et leur utilisation cosmetique |
US7887824B2 (en) | 2004-11-30 | 2011-02-15 | L'oreal | Sulfamide derivatives and cosmetic use thereof |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
AU2006271653A1 (en) * | 2005-07-22 | 2007-01-25 | Boehringer Ingelheim International Gmbh | Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes |
UY30082A1 (es) | 2006-01-11 | 2007-08-31 | Boehringer Ingelheim Int | Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos |
JP2009167103A (ja) * | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | ピラゾリル5−チオグリコシド化合物 |
PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP2076503B1 (en) | 2006-05-19 | 2013-07-17 | Taisho Pharmaceutical Co., Ltd | C-phenyl glycitol compound for the treatment of diabetes |
JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
CA2655937A1 (en) | 2006-06-29 | 2008-01-03 | Taisho Pharmaceutical Co., Ltd. | C-phenyl 1-thioglucitol compound |
WO2008072726A1 (ja) | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-フェニル 1-チオ-d-グルシト-ル誘導体 |
KR101506935B1 (ko) * | 2007-04-02 | 2015-03-31 | 테라코스, 인코포레이티드 | 벤질릭 글리코시드 유도체 및 사용 방법 |
CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AR068016A1 (es) | 2007-08-23 | 2009-10-28 | Theracos Inc | Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
KR101416561B1 (ko) * | 2007-12-27 | 2014-07-08 | 깃세이 야쿠힌 고교 가부시키가이샤 | 피라졸 유도체의 모노세박산염 |
RU2530494C2 (ru) | 2008-08-22 | 2014-10-10 | Теракос, Инк. | Способ получения ингибиторов sglt2 |
PT2334687E (pt) * | 2008-08-28 | 2012-04-13 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
SI2395983T1 (sl) | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
CN102414191B (zh) | 2009-02-23 | 2014-04-16 | 大正制药株式会社 | 4-异丙苯基山梨醇化合物作为sglt1抑制剂 |
EP2298782A1 (en) * | 2009-08-26 | 2011-03-23 | Sanofi-Aventis | Method for producing pyrazole glycoside derivatives |
US8147801B2 (en) | 2009-09-15 | 2012-04-03 | Janssen Pharmaceutica, N.V. | Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion |
ES2546762T3 (es) | 2009-09-30 | 2015-09-28 | Boehringer Ingelheim International Gmbh | Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo |
JP5736377B2 (ja) * | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法 |
AU2010302642A1 (en) * | 2009-10-02 | 2012-04-26 | Sanofi | Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases |
US10610489B2 (en) * | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
RS53827B1 (en) | 2009-11-02 | 2015-06-30 | Pfizer Inc. | DIOKSA-BICYCLE DERIVATIVES [3.2.1] OCTOBER-2,3,4-TRIOLA |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
BR112013000626B1 (pt) | 2010-07-09 | 2019-11-26 | Bhv Pharma Inc | formulação farmacêutica e método para preparar uma forma de dosagem da mesma |
JP2013224263A (ja) * | 2010-08-19 | 2013-10-31 | Taisho Pharmaceutical Co Ltd | 4−イソプロピルフェニルグルシトール化合物 |
EP2607360B1 (en) | 2010-08-20 | 2015-08-19 | Taisho Pharmaceutical Co., Ltd. | 4-Isopropyl-6-methoxyphenyl glucitol compound |
US8822674B2 (en) | 2010-08-20 | 2014-09-02 | Taisho Pharmaceutical Co., Ltd | Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2012176804A1 (ja) * | 2011-06-20 | 2012-12-27 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体 |
AU2012280508A1 (en) | 2011-07-01 | 2013-12-12 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
TW201425326A (zh) * | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
RU2648467C2 (ru) | 2013-02-04 | 2018-03-26 | Тайсо Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое лекарственное средство для лечения запора |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EA033286B1 (ru) | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
AR098670A1 (es) * | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
CN110054657B (zh) * | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | 吡喃葡萄糖取代的吡唑化合物及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1083335A (en) * | 1976-05-10 | 1980-08-12 | Chemed Corporation | Composition and method of inhibiting corrosion |
US5274111A (en) * | 1992-04-07 | 1993-12-28 | American Home Products Corporation | Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof |
CA2300211A1 (en) | 1997-08-27 | 1999-03-04 | Masato Iwasaki | Sustained-release oral preparation |
JP2001523704A (ja) | 1997-11-25 | 2001-11-27 | バイエル・アクチエンゲゼルシヤフト | α−グルコシダーゼ阻害剤を含んで成る持続放出性製剤 |
NZ514661A (en) * | 1999-04-06 | 2003-06-30 | Sankyo Co | alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions |
JP2001002567A (ja) | 1999-04-20 | 2001-01-09 | Takeda Chem Ind Ltd | 水溶性薬物を含有する徐放性製剤 |
SK286600B6 (sk) * | 1999-08-31 | 2009-02-05 | Kissei Pharmaceutical Co., Ltd | Glukopyranozyloxypyrazolové deriváty, farmaceutická zmes s ich obsahom a medziprodukty na ich výrobu |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
EP1338603B1 (en) * | 2000-11-02 | 2010-01-20 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
AU2002225356B2 (en) * | 2000-12-28 | 2008-03-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
MXPA05001549A (es) * | 2002-08-08 | 2005-05-05 | Kissei Pharmaceutical | Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion. |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
CA2500873C (en) * | 2002-10-04 | 2012-01-17 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
JP4285338B2 (ja) * | 2004-06-14 | 2009-06-24 | トヨタ自動車株式会社 | スターリングエンジン |
-
2003
- 2003-08-07 MX MXPA05001549A patent/MXPA05001549A/es active IP Right Grant
- 2003-08-07 EP EP03784564A patent/EP1544208B1/en not_active Expired - Lifetime
- 2003-08-07 AT AT03784564T patent/ATE469161T1/de not_active IP Right Cessation
- 2003-08-07 WO PCT/JP2003/010048 patent/WO2004014932A1/ja active Application Filing
- 2003-08-07 ES ES03784564T patent/ES2345250T3/es not_active Expired - Lifetime
- 2003-08-07 DE DE60332743T patent/DE60332743D1/de not_active Expired - Lifetime
- 2003-08-07 KR KR1020057002286A patent/KR100985502B1/ko not_active IP Right Cessation
- 2003-08-07 BR BRPI0313290A patent/BRPI0313290B1/pt not_active IP Right Cessation
- 2003-08-07 AU AU2003254847A patent/AU2003254847B2/en not_active Ceased
- 2003-08-07 JP JP2004527355A patent/JP4540475B2/ja not_active Expired - Fee Related
- 2003-08-07 NZ NZ538117A patent/NZ538117A/en not_active IP Right Cessation
- 2003-08-07 PL PL375473A patent/PL213095B1/pl unknown
- 2003-08-07 CA CA2494179A patent/CA2494179C/en not_active Expired - Fee Related
- 2003-08-07 RU RU2005106259/04A patent/RU2356906C2/ru not_active IP Right Cessation
- 2003-08-07 US US10/523,820 patent/US7375087B2/en not_active Expired - Fee Related
- 2003-08-08 TW TW092121803A patent/TW200413401A/zh not_active IP Right Cessation
-
2005
- 2005-02-08 IL IL16674805A patent/IL166748A0/xx active IP Right Grant
- 2005-03-08 NO NO20051209A patent/NO330456B1/no not_active IP Right Cessation
-
2006
- 2006-02-27 HK HK06102572A patent/HK1082743A1/xx not_active IP Right Cessation
-
2008
- 2008-04-17 US US12/104,890 patent/US7655632B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2345250T3 (es) | 2010-09-20 |
IL166748A0 (en) | 2006-01-15 |
MXPA05001549A (es) | 2005-05-05 |
US7655632B2 (en) | 2010-02-02 |
BRPI0313290B1 (pt) | 2016-12-06 |
KR100985502B1 (ko) | 2010-10-05 |
RU2005106259A (ru) | 2005-08-27 |
CA2494179A1 (en) | 2004-02-19 |
AU2003254847B2 (en) | 2009-06-04 |
EP1544208B1 (en) | 2010-05-26 |
KR20050059067A (ko) | 2005-06-17 |
US20060166899A1 (en) | 2006-07-27 |
PL213095B1 (pl) | 2013-01-31 |
PL375473A1 (en) | 2005-11-28 |
US7375087B2 (en) | 2008-05-20 |
WO2004014932A1 (ja) | 2004-02-19 |
ATE469161T1 (de) | 2010-06-15 |
CA2494179C (en) | 2012-04-24 |
NO20051209L (no) | 2005-04-15 |
TWI341843B (pt) | 2011-05-11 |
NZ538117A (en) | 2007-01-26 |
NO330456B1 (no) | 2011-04-18 |
DE60332743D1 (de) | 2010-07-08 |
RU2356906C2 (ru) | 2009-05-27 |
JPWO2004014932A1 (ja) | 2005-12-02 |
JP4540475B2 (ja) | 2010-09-08 |
EP1544208A4 (en) | 2007-05-02 |
US20080312153A1 (en) | 2008-12-18 |
AU2003254847A1 (en) | 2004-02-25 |
HK1082743A1 (en) | 2006-06-16 |
TW200413401A (en) | 2004-08-01 |
EP1544208A1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313290A (pt) | Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produção | |
EP1609798A4 (en) | CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF | |
NO20020968L (no) | Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav | |
WO2002044192A1 (fr) | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions | |
WO2002028872A1 (fr) | Derives de glucopyranosiloxybenzylbenzene et compositions therapeutiques contenant ces composes | |
EP1400529A4 (en) | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF | |
WO2002055496A8 (en) | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | |
WO2004026863A8 (en) | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors | |
DK1270584T3 (da) | Glucopyranosyloxybenzylbenzenderivater, medicinske sammensætninger indeholdende samme og intermediater til fremstilling af derivaterne | |
SE0102299D0 (sv) | Compounds | |
SE0102300D0 (sv) | Compounds | |
EP1637539A4 (en) | PYRAZOL DERIVATIVE MEDICAMENT COMPOSITION CONTAINING THEREOF AND INTERMEDIATE PRODUCT FOR THE PRODUCTION THEREOF | |
BRPI0409109A (pt) | novos compostos | |
ATE381535T1 (de) | Phenethanolaminderivate | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
JO2493B1 (en) | New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses | |
ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
SE0400043D0 (sv) | New compounds | |
NO20040881L (no) | Orale antidiabetes midler. | |
AU9233101A (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
BR9917315A (pt) | Composições medicinais para liberação imediata para uso oral | |
IL169577A0 (en) | Oligosaccharide derivatives and pharmaceutical compostions containing the same | |
MY135855A (en) | "pyrrolopyrimidinone derivatives, process of preparation and use" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/12/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |